-
About Me
Alison Bass is a Pulitzer Prize nominee and author of Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, which won the NASW Science in Society Award. She was a longtime medical and science writer for The Boston Globe and has also written for The Miami Herald, Psychology Today and MIT's Technology Review, among other publications. A series she wrote for The Boston Globe on psychiatry was nominated for a Pulitzer Prize and she has received many other journalism awards. In 2007, she won a prestigious Alicia Patterson Fellowship to write Side Effects. Bass teaches journalism at Mount Holyoke College and Brandeis University.
Tag Archives: Congress
Fast-moving bill in Congress would weaken FDA oversight of new drugs and devices
Share Congress is moving quickly to pass a bill that would authorize higher industry fees for the FDA in exchange for speeding up the approval of some drugs and medical devices and eliminating restrictions on financial conflicts of interest among … Continue reading
Is the FDA violating its own mandate to approve safe drugs?
Share Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at … Continue reading
Posted in antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized
Tagged antidepressants, clinical trials, Congress, Donald Light, FDA, Massachusetts Legislature, me-too drugs, off-label use, pipeline, safety and effectiveness of drugs
2 Comments
Enforcing anti-kickback laws: a powerful deterrent against ghost-writing in medicine
Share The Obama administration recently made it clear that it will require drug companies to disclose the payments they make to doctors for research, consulting, speaking, travel and entertainment under the new health care law — see the New York … Continue reading
Posted in antidepressants, conflicts of interest, continuing medical education, drug marketing, ghostwriting, pharmaceutical industry, university industry collaboration
Tagged anti-kick statutes, conflicts of interest in medicine, Congress, continuing medical education, corruption, drug and medical device companies
Leave a comment